Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Department of Urology, Goethe University, University Hospital Frankfurt, Theodor- Stern Kai 7, 60590, Frankfurt, Germany.
Int Urol Nephrol. 2023 May;55(5):1117-1123. doi: 10.1007/s11255-023-03517-0. Epub 2023 Feb 23.
It is unknown to what extent overall survival (OS) of organ-confined (T2N0M0) urothelial carcinoma of the urinary bladder (UCUB) patients differs from age- and sex-matched population-based controls, especially when treatment modalities such as radical cystectomy (RC), trimodal therapy (TMT), or radiotherapy (RT) are considered.
Relying on the Surveillance Epidemiology and End Results database (2004-2018), we identified newly diagnosed (2004-2013) T2N0M0 UCUB patients treated with either RC, TMT or RT. For each case, we simulated an age- and sex-matched control (Monte Carlo simulation), relying on Social Security Administration Life Tables with 5 years of follow-up, and compared OS with that of RC-, TMT-, and RT-treated cases. Additionally, we relied on smoothed cumulative incidence plots to display cancer-specific mortality (CSM) and other-cause mortality (OCM) rates for each treatment modality.
Of 7153 T2N0M0 UCUB patients, 4336 (61%) underwent RC, 1810 (25%) TMT, and 1007 (14%) RT. At 5 years, OS rate in RC cases was 65% vs. 86% in population-based controls (Δ = 21%); in TMT cases, 32% vs. 74% in population-based controls (Δ = 42%); and in RT, 13% vs. 60% in population-based control (Δ = 47%). Five-year CSM rates were highest in RT (57%), followed by TMT (46%) and RC (24%). Five-year OCM rates were the highest in RT (30%), followed by TMT (22%) and RC (12%).
OS of T2N0M0 UCUB patients is substantially less than that of age- and sex-matched population-based controls. The biggest difference affects RT, followed by TMT. A modest difference was recorded in RC and population-based controls.
目前尚不清楚局限于器官(T2N0M0)的膀胱癌(UCUB)患者的总生存(OS)与年龄和性别匹配的基于人群的对照相比有何不同,特别是在考虑根治性膀胱切除术(RC)、三联疗法(TMT)或放射治疗(RT)等治疗方式时。
利用监测、流行病学和最终结果数据库(2004-2018 年),我们确定了新诊断为 T2N0M0UCUB 并接受 RC、TMT 或 RT 治疗的患者。对于每个病例,我们都根据社会安全管理局的寿命表(5 年随访)进行了年龄和性别匹配的模拟对照(蒙特卡罗模拟),并将 OS 与 RC、TMT 和 RT 治疗病例的 OS 进行了比较。此外,我们还依赖于平滑累积发生率图来显示每种治疗方式的癌症特异性死亡率(CSM)和其他原因死亡率(OCM)。
在 7153 例 T2N0M0UCUB 患者中,4336 例(61%)接受 RC 治疗,1810 例(25%)接受 TMT 治疗,1007 例(14%)接受 RT 治疗。在 5 年时,RC 病例的 OS 率为 65%,而人群对照的 OS 率为 86%(Δ=21%);在 TMT 病例中,OS 率为 32%,而人群对照的 OS 率为 74%(Δ=42%);在 RT 病例中,OS 率为 13%,而人群对照的 OS 率为 60%(Δ=47%)。5 年 CSM 率在 RT 中最高(57%),其次是 TMT(46%)和 RC(24%)。5 年 OCM 率在 RT 中最高(30%),其次是 TMT(22%)和 RC(12%)。
T2N0M0UCUB 患者的 OS 明显低于年龄和性别匹配的基于人群的对照。最大的差异影响 RT,其次是 TMT。RC 和人群对照之间存在适度差异。